Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...

BOSTON, April 01, 2026 (GLOBE NEWSWIRE)-- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 ...

Last week, readers heard from the Democratic candidates for the Third Congressional District (CD3) race. Now, it’s time to hear from the Republican incumbent, Representative Lauren Boebert, and GOP ...

Tiziana Life Sciences Ltd. (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced acceptance of a ...

Tiziana’s intranasal foralumab has previously demonstrated favorable safety and signals of clinical benefit in an expanded access program in non-active secondary progressive multiple sclerosis, with ...

ROYERSFORD, Pa.--(BUSINESS WIRE)--Abzyme Therapeutics LLC, a biotech company focused on developing antibodies for diagnostic and therapeutic applications, has filed a patent application entitled ...

After George Santos turned his scheming and expulsion from the House of Representatives into a national reality show, coverage of the election to replace him now is being framed as a picture window on ...

A short course of anti-CD3 antibody therapy decreases the insulin needs of patients with type 1 diabetes mellitus (T1DM) during the first few years after diagnosis, new data of a phase II trial reveal ...

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical Products Administration (NMPA) has accepted the ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the American Association for Cancer ...